Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
American Journal of Hematology|March 13, 2019
Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot studyBrigitte Pegourie, Lionel Karlin, Lotfi Benboubker, et al.
Cancer Medicine|August 7, 2023
Clinical outcome of therapy-related acute myeloid leukemia patients. Real-life experience in a University Hospital and a Cancer Center in FranceAmine Belhabri, Mael Heiblig, Stephane Morisset, et al.
Current Research in Translational Medicine|February 10, 2026
Real-world treatment and long-term outcomes after autologous stem cell transplantation in first line for myeloma in France and Algeria before the daratumumab eraEmilie Martin, Stéphane Morisset, Mohamad Sobh, et al.
The New England Journal of Medicine|June 3, 2025
Measurable Residual Disease-Guided Therapy in Newly Diagnosed MyelomaAurore Perrot, Jérôme Lambert, Cyrille Hulin, et al.
Endoscopy|July 23, 2020
Narrow-band imaging versus Lugol chromoendoscopy for esophageal squamous cell cancer screening in normal endoscopic practice: randomized controlled trialMélissa Gruner, Angélique Denis, Claude Masliah, et al.
Blood|April 21, 2024
RAS/RAF landscape in monoclonal plasma cell conditionsAnais Schavgoulidze, Jill Corre, Mehmet Kemal Samur, et al.
Blood|September 24, 2025
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencingAnaïs Schavgoulidze, Aurore Perrot, Xavier Leleu, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2020
High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCRSouad Assaad, Virginie Avrillon, Marie-Line Fournier, et al.
Blood|January 22, 2025
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS TrialAurore Perrot, Cyrille Touzeau, Jerome Lambert, et al.
Haematologica|April 20, 2023
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 studyAlexis Talbot, Arthur Bobin, Léa Tabone, et al.
Pageof 3